Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.
Research output: Contribution to journal › Article
Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the monoclonal antibody H16.V5. To investigate the importance of this epitope for overall immunogenicity of HPV-16, HPV-16 virus-like particles devoid of the H16.V5 epitope were engineered by site-directed mutagenesis of ten non-conserved, surface-exposed residues. Removal of the H16.V5-defined epitope had only a marginal effect on antigenic reactivity with antibodies in sera from infected subjects, but affected immunogenicity in experimental immunization of mice, with reduced induction of both antibody responses and CTL responses.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal of General Virology|
|Issue number||Pt 3|
|Publication status||Published - 2007|
Related research output
Janka Ryding, 2008, Department of Laboratory Medicine, Lund University. 159 p.
Research output: Thesis › Doctoral Thesis (compilation)